

# A Step Forward in the Minimally Invasive Treatment of Tendinopathy and Bony Prominences.

For podiatry patients with chronic tendinopathy or painful bony prominences, the Tenex Health TX® System can be a game changer. It employs advanced ultrasonic technology and image guidance to percutaneously cut and remove symptomatic tissue, including bone, through a mini incision. This single-procedure solution has the potential to help patients heal faster, less invasively and with less discomfort than open surgery - in soft tissue procedures.¹

Procedures using the Tenex Health TX® System are covered by most insurance.

The Tenex Health TX® System is clinically proven in soft tissue to relieve pain in ≥85% of patients² and allow a return to activity in typically 6-8 weeks.






#### **Soft Tissue Removal**

Chronic refractory tendinopathy (TX1, TX2 and TX-Bone MicroTips\*):

- · Achilles insertion
- Peroneal
- Plantar fasciosis
- Plantar fibroma
- · Failed surgical intervention






### **Bone and Calcific** Tissue Removal

The TX-Bone MicroTip is the latest FDA cleared addition, designed to remove bone and calcific tissue.\*

Calcification/osteophytes/spur formations (TX-Bone MicroTip):

- Achilles tendon insertion/ Haglund's deformity
- Plantar fascia insertion spur
- Exostoses and spurs
- Diabetic foot ulcer





#### **Diabetic Foot Ulcer Application**

TXB can be used to treat the root cause of diabetic foot ulcers (DFU) without entering or expanding the wound area.

- Removes bony prominences and dense scar tissue subcutaneously
- Provides the perfusion needed to regenerate healthy tissue<sup>3</sup>

## Clinical Experience

Tenex Health TX® System used to treat 105 DFU patients, all with prior advanced wound care.4+

- 96% of patients healed
- Recurrence rate < 5%
- Average healing time 3.5 weeks
- 6-year experience

No Recurrence > 24 mo<sup>3</sup>





Pre-Treatment

14 Days After

MicroTip Specifications and Characteristics		<b>Tip Gauge</b> (approximate inner lumen OD)	Sheath Gauge (approximate outer lumen max OD)	Volume as Percentage of TX1 Baseline (per stroke @26.5 kHz)	Tissue Indications
TX1 MicroTip 25.4 mm		19 (1.1 mm)	11 (3.0 mm)	100%	Soft Only
TX2 MicroTip 43.2 mm	<b></b>	18 (1.3 mm)	14 (2.1 mm)	200%	Soft Only
<b>TX-Bone MicroTip</b> (TXB) 33.0 mm		15 (1.9 mm)	11 (3.0 mm)	650%	Soft + Hard

- 1. Stuhlman CR, et al. Orthopedics 2016;39(6):e1028-e1035.; Yanish GJ, et al. Submitted, J Shoulder Elbow Surg, 2019 Apr.
- 2. Baker CL, Mahoney JR. The Orthopaedic Journal of Sports Medicine 2020;8(3):1-8.; Battista CT, et al. Tech in Hand and Upper Extrem Surg 2018;22:15-18.; Chimenti RL, et al. J Ultrasound Med 2019;39(6):1629-1635.; Elattrache NS, Morrey BF. Operat Tech Orthop 2013;23(2):98-103.; Freed L, et al. J Am Podiatr Med Assoc. 2019;109(1):1-8.; Khanna M, et al. Poster presented at: Annual Meeting American Academy of Phys Medicine & Rehabilitation 2013 Oct.; Koh JSB, et al. Am J Sports Med 2013;41(3):636-644.; Patel MM, et al. J Orthop Rheum 2015;2(2):1014.; Patel MM. Am J of Orthop 2015;44(3):107-110.; Razdan R, Vander Woude E. J Surg Proced Tech 2018;3(102):1-6.; Seng C, et al. Am J Sports Med 2016;44(2):504-510.; Yanish GJ, et al. Submitted, J Shoulder Elbow Surg, 2019 Apr.
- 4. Freed L. Diabetes 2020 Jun;69(Supplement 1).
- \* TXB has greater potential than TX1 or TX2 for faster and more tissue removal.
- † Studies were the independent work of the participating physicians and were not promoted by Tenex Health, Inc. in any way. Tenex Health, Inc. does not promote use of the TX1 MicroTip or TX2 MicroTip for the treatment of hard tissue pathology or diabetic foot ulcers. The TX-Bone (TXB) MicroTip was developed, indicated, and FDA cleared for the treatment of hard tissue pathology and diabetic foot ulcers.

For more information, contact Tenex Health 949.454.7500 855.2TENDON • info@tenexhealth.com tricemedical.com • tenexhealth.com



TENEX | Tenex Health is now a part of Trice Medical

Tenex Health, Tenex Health TX®, and the Tenex Health logo are trademarks of Tenex Health, Inc.